Martínez Miguel Angel
Fundacio irsiCaixa, Universitat Autònoma de Barcelona, Spain.
Methods Mol Biol. 2009;487:343-68. doi: 10.1007/978-1-60327-547-7_17.
Therapeutic options against the human immunodeficiency virus type 1 (HIV-1) continue to expand with the development of new drugs and new therapeutic strategies. Nevertheless, management of HIV-1 infected individuals has become increasingly complex. The emergence of drug-resistant variants, the growing recognition of the long-term toxicity of antiretroviral therapies and the persistence of viral reservoirs justify the continued efforts to develop new anti-HIV-1 strategies. Recent advances regarding the utility of RNA-mediated interference (RNAi) to specifically inhibit HIV-1 replication have opened new possibilities for the development of gene-based therapies against HIV-1 infection. Here, the recent advances in siRNA-based therapies are reviewed.
随着新药和新治疗策略的发展，针对人类免疫缺陷病毒1型（HIV-1）的治疗选择不断增加。然而，对HIV-1感染者的管理变得越来越复杂。耐药变异体的出现、对抗逆转录病毒疗法长期毒性的日益认识以及病毒储存库的持续存在，都证明了继续努力开发新的抗HIV-1策略的合理性。最近关于RNA介导的干扰（RNAi）特异性抑制HIV-1复制的效用的进展，为开发针对HIV-1感染的基因疗法开辟了新的可能性。在此，对基于小干扰RNA（siRNA）疗法的最新进展进行综述。
